Cancer Biology Program, University of Hawaii Cancer Center, University of Hawaii at Manoa, Hawaii, USA.
Laboratory of Molecular Biology, Faculty of Pharmacy, Meijo University, Nagoya, Japan.
Prostate. 2022 Jun;82(10):1025-1039. doi: 10.1002/pros.24348. Epub 2022 Apr 1.
Prostate cancer is a bone metastatic cancer and is the second leading cause of cancer-related death in men. Prolonged progression-free survival of prostate cancer patients is associated with high regucalcin expression in the tumor tissues. This study investigates the underlying mechanism by which regucalcin prevents bone metastatic activity of prostate cancer cells.
Human prostate cancer PC-3 or DU-145 wild-type cells or regucalcin-overexpressing PC-3 or DU-145 cells (transfectants) were cultured in Dulbecco's modified Eagle's medium containing 10% fetal bovine serum.
Overexpressed regucalcin suppressed the migration and invasion of bone metastatic human prostate cancer cells in vitro, and it reduced the levels of key proteins in metastasis including Ras, Akt, MAPK, RSK-2, mTOR, caveolin-1, and integrin β1. Invasion of prostate cancer cells was promoted by coculturing with preosteoblastic MC3T3-E1 or preosteoclastic RAW264.7 cells. Coculturing with cancer cells and bone cells repressed the growth of preosteoblastic cells and enhanced osteoclastogenesis of preosteoclastic cells, and these alterations were caused by a conditioned medium from cancer cell culture. Disordered differentiation of bone cells was prevented by regucalcin overexpression. Production of tumor necrosis factor-α (TNF-α) in cancer cells was blocked by overexpressed regucalcin. Of note, the effects of conditioned medium on bone cells were prevented by NF-κB inhibitor. TNF-α may be important as a mediator in the crosstalk between cancer cells and bone cells.
Overexpression of regucalcin suppressed the migration, invasion, and bone metastatic activity of human prostate cancer cells. This study may provide a new strategy for therapy with the regucalcin gene transfer.
前列腺癌是一种骨转移性癌症,是男性癌症相关死亡的第二大主要原因。前列腺癌患者无进展生存期延长与肿瘤组织中高表达钙调节蛋白有关。本研究探讨了钙调节蛋白防止前列腺癌细胞发生骨转移活性的潜在机制。
在含 10%胎牛血清的 Dulbecco 改良 Eagle 培养基中培养人前列腺癌 PC-3 或 DU-145 野生型细胞或钙调节蛋白过表达 PC-3 或 DU-145 细胞(转染细胞)。
过表达的钙调节蛋白抑制体外骨转移性人前列腺癌细胞的迁移和侵袭,并降低转移相关关键蛋白的水平,包括 Ras、Akt、MAPK、RSK-2、mTOR、窖蛋白-1 和整合素β1。与成骨前体细胞 MC3T3-E1 或破骨前体细胞 RAW264.7 共培养可促进前列腺癌细胞的侵袭。与癌细胞和骨细胞共培养抑制成骨前体细胞的生长并增强破骨前体细胞的破骨细胞生成,这些变化是由癌细胞培养的条件培养基引起的。骨细胞的异常分化被钙调节蛋白过表达所阻止。过表达钙调节蛋白可阻断肿瘤坏死因子-α(TNF-α)在癌细胞中的产生。值得注意的是,NF-κB 抑制剂可阻止条件培养基对骨细胞的作用。TNF-α可能是癌细胞和骨细胞之间串扰的重要介质。
钙调节蛋白的过表达抑制了人前列腺癌细胞的迁移、侵袭和骨转移活性。本研究可能为钙调节蛋白基因转移的治疗提供新策略。